Article No
SYN-1212-M005
Specifications
| CAS No | 1423715-09-6 |
| MW | 437.9 |
| Article No | SYN-1212-M005 |
| Country Availability | SE, FI, DK, NO, IS, EE, LV, LT |
| Description | SP2509 |
| Supplier | Adipogen Life Sciences |
| Format | Powder |
| Notes | Chemical. CAS: 1423715-09-6. Formula: C19H20ClN3O5S. MW: 437.9. LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells. SP-2528 is a selective and reversible LSD1 inhibitor with an IC(50) of 10nM. SP-2528 demonstrates a high specificity for LSD1, with no effect on MAOi.|LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells. SP-2528 is a selective and reversible LSD1 inhibitor with an IC(50) of 10nM. SP-2528 demonstrates a high specificity for LSD1, with no effect on MAOi. |
| Molecular Formula | C19H20ClN3O5S |
| Alias Names | SP-2509 |
| Product Type | Chemicals & Biochemicals |
| Purity | >95% |
| Research area | Epigenetics |
| Shipping Information | RT |
| Size | 5 mg |
| Solubility | Soluble in DMSO. |
| Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Storage | -20°C, 4°C |
| Technical Specifications | Chemical. CAS: 1423715-09-6. Formula: C19H20ClN3O5S. MW: 437.9. LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells. SP-2528 is a selective and reversible LSD1 inhibitor with an IC(50) of 10nM. SP-2528 demonstrates a high specificity for LSD1, with no effect on MAOi. |
| Product Page Updated | 2024-02-01T08:25:01.492Z |
